Company profile
Aprea Therapeutics, Inc.
NASDAQ: APRE · Healthcare · Biotechnology
#1 of 1,422 Healthcare companies by revenue
EA Score
——FH 43DQ —GM —SS 34
v0.1 · 35/100 weight · pillars only
↑ balance-sheet leverage, filing timeliness · ↓ Piotroski F, workforce scale
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
-100.0%
Net income (FY)
-$12.6M
Employees
8
as of 2026-08-23
Market cap
$7.9M
as of 2026-08-23
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Net income-$12.6M-$12.6M2025
Operating income-$13.2M-$13.2M2025
Total assets$15.9M$15.9M2025
Liabilities$3.2M$3.2M2022
Equity$12.4M$12.4M2025
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Aprea Therapeutics, Inc.’s financial profile?
Aprea Therapeutics, Inc. earned -$12.6M in FY2025 net income.
Peers · Healthcare
CNS Pharmaceuticals, Inc.——AEON Biopharma, Inc.——AI Maverick Intel, Inc.——Univec, Inc.——Apimeds Pharmaceuticals US, Inc——Liminatus Pharma, Inc. Class A Common Stock——Neighbors
Suffolk →Key facts
CEOOren Gilad
SectorHealthcare
IndustryBiotechnology
HeadquartersBoston, MA
ExchangeNASDAQ: APRE
Employees8
IPO date2019-10-03
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.